Budesonide dry powder inhaler

DRUG3 trials

Sponsors

NovaMed Pharmaceuticals Inc., Research in Real-Life Ltd, University of Oxford

Conditions

AsthmaCoronavirus Infection

Phase 2

Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma

NovaMed Pharmaceuticals Inc.Asthma

Start: 2010-12-31End: 2011-10-31Target: 332Updated: 2011-08-23

STerOids in COVID-19 Study

TerminatedNCT04416399

University of OxfordCoronavirus Infection

Start: 2020-07-16End: 2021-01-12Updated: 2021-02-08

Unknown Phase

Real Life Effectiveness of Easyhaler (Orion)

CompletedNCT02048930

Research in Real-Life LtdAsthma

Start: 2012-09-30End: 2013-03-31Updated: 2014-01-29

Related Papers

Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19

ERJ Open Research2024-02-204 citations

Nodal analysis determined nasal mucosal-associated mediators were associated with accelerated clinical recovery from SARS-CoV-2 infection

2023-09-09

Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis.

2022-04-0743 citations

Budesonide: A promising candidate therapeutic for early COVID-19

Annals of Medicine and Surgery2021-08-012 citations

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.

2021-04-09287 citations

PECULIARITIES OF CLINICAL MANAGEMENT OF ASTHMA DURING CORONAVIRUS DISEASE (COVID-19) PANDEMIC

Ukrainian Pulmonology Journal2021-01-01